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O r i g i n a l  a r t i c l e
 .Introduction
As of 2011 our laboratory has successfully completed over 4,500 
mouse orthotopic lung transplants as a part of investigator-
initiated studies (1-20) and collaborations with biotechnological 
companies (21-30). While in the beginning of our experience 
technical obstacles were encountered, after an initial learning 
curve complications are now rare (less than 1%, not including 
post-transplantation atelectasis). Other laboratories have 
reported technical success rates of around 80-90% (9,26). As we 
have already described the rudimentary steps of this procedure 
(1,5) , here we will focus only on major surgical complications 
that hinder experimental success. We will also discuss the causes 
of technical failures and steps that can be taken to prevent them.
 .Complications
Pneumothorax
The first type of pneumothorax (Type I pulmonary injury) 
stems from technical errors that occur due to excessive handling 
of the lung. This results in a severe air leak, mostly because of 
a bronchial tear, or damage to the lung surface. This becomes 
evident immediately after graft reperfusion and reaeration. This 
type of injury is worth repairing if the area of injury is small or 
the recipient is a very rare transgenic mouse. Although the mouse 
bronchus and lung tissue are very friable, one can still repair this 
form of damage by placing a shorter cuff on the torn bronchus to 
incorporate the area of damage into the cuff or utilize 10-0 nylon 
suture (Sharpoint AK-D106, Surgical Specialties Corporation, 
Figure 1) to repair a small hole in the donor or recipient 
bronchus. As for tiny defects on the graft surface one can use 
tissue glue to seal it (Webglue, Webster Veterinary Supply Inc, 
Figure 2). In our experience a successful repair of this type of 
injury is easy to achieve and the graft can often be salvaged.
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The second type of pneumothorax (Type II pulmonary 
injury) is more dangerous because the lung injury is small 
and may not be evident immediately upon release of the hilar 
structures. This is usually discovered only after extubation 
of the animal and is often manifested by respiratory distress 
and difficulty in initiating spontaneous respirations. Without 
immediate reintubation the recipient will die within 1 or 2 
minutes and is unlikely to be resuscitated. In order to salvage 
this situation the animal must be quickly reintubated and the 
upper part of the abdomen opened. This will allow immediate 
diagnosis of the problem as either the left or the right side 
of the diaphragm will bulge down with an obvious tension 
pneumothorax. In our experience a Type II pulmonary injury 
can occur either on the side of the transplant or native lung. 
While the reason for this injury can be difficult to determine it 
may be related to the process of mechanical ventilation. In the 
mouse the respiratory rate varies between 60-230 breaths per 
minute (bpm). The tidal volume can vary between 0.09-0.38 
mL/breath resulting in a minute ventilation of 11-36 mL/min 
(31). Despite this physiology our preferred mouse ventilator 
settings include a tidal volume of 0.5 mL and a respiratory rate 
of 110-120 bpm, which yield minute ventilations exceeding the 
normal range. Other laboratories performing similar procedures 
recommend even higher tidal volumes (26). In our experience 
decreasing the minute ventilation for extended portions of 
the procedure leads to poor long-term outcome (unpublished 
data). During single lung ventilation, however, this high volume 
positive-pressure may cause barotrauma and volutrauma, which 
may lead to a Type II pulmonary injury (32). While serious, 
this complication is very rare (from our database we have 
encountered fewer than 20 cases in 5 years), and the severity 
of pulmonary damage is unpredictable. In order to prevent 
this complication we: (I) reduce the tidal volume from 0.5 mL 
to 0.35-0.40 mL when single lung ventilation is initiated and 
maintain this low tidal volume until the lung graft is implanted 
and (II) inflate the lung graft for no more than 1-2 seconds after 
implantation. However, if a pneumothorax does occur the only 
possible treatment is to reintubate the animal immediately, incise 
the upper abdomen and cut a small window in the diaphragm 
to release the air that has collected under tension in the chest. 
After recipient hemodynamics have stabilized the diaphragmatic 
window is left open and the abdominal incision is closed (Figure 
3). If needed, one can close the diaphragm window at a later 
time point. However, it is unlikely that these salvage maneuvers 
will result in a ventilated lung at the time of sacrifice as atelectasis 
will occur after this type of injury. Therefore, mice can generally 
not be used for data generation if this complication arises. 
Figure 1. 10-0 Nylon for suturing tiny hole of bronchus.
Figure 2. Animal Surgical Glue for sealing small air leak of graft lung.
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Graft atelectasis
The anatomy of the mouse lung differs from that of other species 
(33). Total lung capacity (TLC) of the mouse is about 1ml 
compared to 10 ml in the rat. The alveoli of the mouse lung are 
significantly smaller than those of the rat (34) and the airways 
constitute a large percentage of the lung volume in the mouse 
(11%) compared to the rat (5.7%). Cartilage is present in the 
mouse trachea, but is less well organized than in other species. 
Mouse lungs also have fewer respiratory bronchioles and airway 
generations than humans. Two other significant features of 
the mouse lung anatomy are the thinness of the respiratory 
epithelium and the relatively large airway lumen (35). This 
large airway caliber may reduce the flow-resistive load in this 
small animal with a rapid respiratory rate (33). All of these 
characteristics work in favor of preventing atelectasis of the 
mouse lung in comparison to other animal models. Nevertheless, 
it has been brought to our attention that non-alloimmune-
mediated collapse of the grafted lung, which is not associated 
with graft rejection, but rather due to technical problems, is the 
most common complication encountered by other laboratories. 
Thus, in our opinion, pulmonary atelectasis after transplantation 
is generally due to methodologic problems rather than inherent 
anatomic considerations.
Based on our experience and serial sacrifice, pulmonary 
collapse that is unrelated to graft rejection usually occurs on 
the third to fifth post-operative day after transplantation and is 
often not diagnosed until the time of sacrifice. The diagnosis of 
atalectasis is further complicated by the fact that mice do not 
manifest any outward signs of shortness of breath when this 
occurs (6). Furthermore, while non-invasive diagnostic tools 
such as small animal MRI are available to monitor pulmonary 
graft function after transplantation. the routine use of such 
modalities is impractical (Figure 4) (29). Thus, we contend 
that the best method for preventing graft atelectasis is to pay 
meticulous attention to surgical details and rely on several “tricks” 
that we have accumulated over the years in order to prevent this 
complication.  
In our mouse model, we believe pulmonary collapse occurs 
due to two main reasons. The first one involves pathophysiologic 
changes in pulmonary parenchyma after transplantation and 
the second one is technical failure. Graft ischemia-reperfusion 
injury alters graft compliance, increases air flow resistance and 
contributes to atelectatic collapse of the lung (36). Anastomotic 
problems of the small mouse bronchus also can lead to 
atelectasis and anastomotic ischemia followed by remodeling 
and granulation tissue formation, which leads to bronchial wall 
thickening and significant airway obstruction (37-39). Technical 
problems due to poor orientation of the cuff, donor to recipient 
cuff mismatch and other mishaps can lead to atelectatic collapse 
of the lung graft as well. While some have demonstrated that 
cuffing the bronchial anastomosis can be problematic and 
may lead to airway stenosis in the rat (36) the small size of the 
bronchial structures in the mouse makes suturing this structure 
nearly impossible (unpublished observations). Thus, while 
retaining the cuff technique for the bronchial anastomosis we 
have gradually modified the surgical approach and have made 
significant revisions in the method for cuffing this structure. 
First, we now shorten the donor bronchus as close as possible 
to the secondary carina in order to reduce anastomotic ischemia 
and improve the bronchial blood supply (40-43). This type of 
maneuver also results in the need to shorten the venous cuff 
in order to prevent rotation and torsion of the hilar structures. 
Second, we use as big a cuff as possible in order to reduce air 
flow resistance (with gain of experience some microsurgeons 
now cuff most strains of mice with a cuff made from a #18 
angiocatheter instead of a #20 as we had previously described 
(5) (Figure 5). As the hilar anatomy of each strain differs (C3H 
and CBA/Ca mice for example have comparably foreshortened 
hilar structures) the size of the cuff must match each bronchus 
in order to achieve not only optimal ventilation, but also prevent 
venous complications (see below). After these modifications our 
incidence of graft atelectasis has decreased to <5%. 
Pulmonary venous thrombosis
This complication does not usually lead to immediate post-
operative demise and is usually discovered at autopsy either 
due to recipient death before the scheduled sacrifice or at the 
time of sacrifice. Gross appearance of the graft can be diagnostic 
of pulmonary venous thrombosis as the lung is dark red or 
black, is grossly enlarged and firm. Often a clot can be seen in 
the pulmonary vein. At times the right upper lobe of the native 
lung can be involved as well due to propagation of clot. Venous 
thrombosis is usually caused by pulmonary vein torsion or 
compression of the venous outflow from a large bronchus cuff. 
Thus, one must balance the “trade off ” of a large bronchial cuff, 
Figure 3. Diaphragm window for treatment of type II pulmonary injury.
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which results in a lower incidence of graft atelectasis, but a higher 
incidence of pulmonary venous thrombosis. Nevertheless, the 
incidence of this complication can be reduced to very low levels 
by meticulous attention to detail in preventing venous torsion 
and proper cuffing of the hilar structures to reduce rotation of 
the lung by an imbalance between the bronchial and venous 
cuffs.
 .Evaluation
Evaluation of technical success and rejection
 
After technically successful lung transplantation the graft 
should be well aerated and perfused, even in the face of mild 
acute rejection. As mentioned above, unlike cardiac allografts, 
where early technical failure can be manifested by cessation 
of heart beat, the evaluation of the technical success of lung 
transplantation requires either gross inspection after sacrifice or 
radiographic imaging. Conventional imaging modalities, such 
as X-rays, lung perfusion scintigraphy or angiography may be 
Figure 4. MRI images obtained 3 days after lung transplantation reveal ventilation of lung graft on three serial coronal images (top) and graft 
atelectasis in a different animal (bottom).  As previously described (29) aerated lung looks black on MRI due to lack of signal intensity while 
a consolidated lung looks white due to the high intensity of this water-rich structure when atelectatic.
Figure 5. Adjustment of bronchus cuff size. From L to R, the size 
is 18#, 20# and 24#, which are used for bronchus, pulmonary vein, 
and pulmonary artery, respectively.
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useful in humans and large animals, but are not practical for large 
throughput experiments in mice (44-48). Either the resolution 
of these techniques is not suitable to evaluate subtle pathological 
changes, or the techniques cannot be performed on a serial 
basis in the same animal (36). Greschus suggested Flat-Panel 
Volumetric Computer Tomography (fpVCT) as a precise tool 
to assess the success of rat orthotopic lung transplantation that 
can be used to follow the process of graft rejection with very high 
spatial resolution (36). Such a technique, however, might not be 
applicable to the mouse due to its small size. We have recently 
focused on small animal MRI to evaluate pulmonary pathology 
and have found this technique to be a highly reproducible 
non-invasive approach to visualize anatomic pathology of the 
lung such as pulmonary collapse due to either advanced acute 
rejection or atelectasis (29) (Figure 4). However, we realize that 
this modality might not be easily accessible to all laboratories 
and thus to date there still is no easily accessible, effective 
and precise imaging modality to evaluate the grafted lung for 
technical success or rejection. Our current practice thus relies on 
grading rejection based on strict histologic criteria, which mirror 
human graft evaluation. In 1990, the International Society for 
Heart and Lung Transplantation (ISHLT) adopted a “Working 
Formulation of the Standardization of the Nomenclature in the 
Diagnosis of Lung Rejection,” which was revised in 1996 and 
again in 2007 (49). We have thus adapted this grading scale for 
the mouse model (Table 1).  The development of better imaging 
modalities in the future may facilitate serial monitoring of graft 
outcome and early detection of technical failures.
Evaluation of graft function
Mouse orthotopic lung transplantation is a very useful model 
not only because it mimics human lung transplantation, but 
because the investigator can collect samples that mimic clinical 
investigations of human lung transplant recipients, such as 
arterial blood gases (ABGs), bronchioalveolar lavages (BALs), 
and lung parenchymal tissue. The most important tests, such as 
spirometry and plethysmography have been reported by some 
groups (21,50), but are not currently routinely used by us. To 
date our laboratory has relied mostly on arterial blood gas (ABG) 
measurement of a mouse supported solely by the lung graft after 
hilar clamping of the native lung to evaluate function as well 
as bronchoalveolar lavage, wet dry ratio, histology, FACS, and 
immunohistochemistry. We have focused on these tests as they 
mirror the techniques of periopertaive graft assessment used in 
the clinics. Some of these techniques are described below.
Arterial Blood Gas measurement(ABG)
Our laboratory has relied on ABG measurement to assess graft 
function (1,6,16,18,19).
(I) Anesthetize the recipient mouse with an intraperitoneal 
(i.p) injection of Ketamine (5-6 μg/g) and Xylazine (7-8 μg/g). 
This is about 2/3 of the regular dose used during the actual 
transplantation procedure as often after transplantation the 
recipient cannot tolerate a regular dose of anesthetics (5).
(II) Initiate mechanical ventilation of both lungs with 100% 
FiO2 for 4 minutes prior to hilar clamping.
(III) Occlude the hilum of the native non-transplanted lung 
(use either a clip or a 6-0 silk tie. Figures 6, 7) and ventilate 4 to 
10 more minutes prior to drawing blood.
Here, the microsurgeon needs to detach the right lower 
lobe from the esophagus very carefully and free the entire right 
lung (in case of left lung transplantation) from connective 
tissue without bleeding. The total circulating blood volume in 
the mouse is only around 2 mL (6-8% of whole body weight), 
and literally any blood loss will affect hemodynamics, result 
in circulatory instability and impact the ABG measurement. 
Ventilate both lungs for 4 minutes before occluding the native 
right lung in order to assess the function of the graft. The 
duration of single lung ventilation prior to drawing ABG is 
Table 1. Classification and grading of pulmonary allograft rejection.
A: Acute rejection with/without B:. Airway inflammation-lymphocytic bronchitis/bronchiolitis
Grade 0:   None Grade X:   Ungradeable
Grade 1:   Minimal Grade 0:    None
Grade 2:   Mild Grade 1R:   Low grade
Grade 3:   Moderate Grade 2R:   High grade
Grade 4:   Severe
C: Chronic airway rejection: bronchiolitis obliterans
 0:   Absent
1:   Present 
D: Chronic vascular rejection: accelerated graft vascular sclerosis
“R” denotes revised grade to avoid confusion with 1996 scheme. Stewart, S, Fishbein, MC, Snell, GI, et al. Revision of the 1996 working 
formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26:1229
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controversial and must be tailored based on experimental 
conditions (1,26). After transplantation either ischemia-
reperfusion injury or graft rejection can cause severe lung graft 
dysfunction. Poor oxygenation as a result of this type of injury 
can lead to myocardial ischemia, heart failure, and death in 
approximately 10 minutes. As mice consume large quantities 
of O2 even at rest (31,33), the fall in PaO2 and the associated 
oxyghemoglobin desaturation occurs fairly rapidly (51). Thus, 
in our experience drawing the ABG after 4 to 10 minutes of 
single lung ventilation will allow for a sensitive assessment of 
graft function with reliable and reproducible data obtained 
by matching the period of single lung ventilation between 
experimental and control groups. 
(IV) Use a 1mL heparin coated syringe with 25 G needle to 
draw blood from the left ventricle or ascending aorta to measure 
ABG.
Broncho-alveolar lavage (BAL)
BAL is used to analyze the influx of inflammatory cells into the 
airways after  human lung transplantation (52) and has been 
used by our laboratory to assess lung grafts (3,53). Using current 
techniques BAL fluid collection originates from both right and 
left lung as the lavage is performed with an open chest while 
intubating the main trachea (Figure 8). The advantage of this 
technique is that it is easy to perform but the disadvantage is that 
it mixes the airway cell infiltrates of the native and transplanted 
lung. Nevertheless, our data describe that airway inflammatory 
cells, such as neutrophils, correlate with tissue infiltration in 
the transplanted lung (4) and thus we have routinely utilized 
tracheal BAL to sample the airways and are currently developing 
methods to use a longer catheter that can be inserted into either 
Figure 6. Occlude the hilum of native non-transplanted lung with clip.
Figure 7. Occlude the hilum of native non-transplanted lung with 
6-0 silk.
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Figure 8. The current method for BAL.
the left or right lung selectively.  Alternatively one can occlude 
the native lung in order to collect the BAL sample exclusively 
from the graft.
Two-photon microscopy
As the lung is constantly exposed to both innocuous and potentially 
noxious antigens, a thorough understanding of both innate and 
adaptive immune responses in this organ is essential (30). Two-
photon microscopy has evolved into a powerful tool that 
can allow for observation of cellular interactions in real time. 
Such a technique has allowed us to substantially extend our 
understanding of immune responses (54-59). Recently, our 
group has expanded 2-photon microscopy to the study of 
the inflammatory responses in the lung, which has allowed 
us to study ischemia reperfusion injury in vivo (28,55,56). 
By relying on this approach we were able to demonstrate 
that, contrary to popular belief, monocytes coordinate the 
transendothelial migration of neutrophils into inflamed tissue. 
We determined that depletion of blood monocytes impairs 
neutrophil recruitment to the lung, which could have important 
implications for the design of therapeutic strategies to treat 
inflammatory lung diseases (28). Based on this experience, we 
have expanded the use of intravital two-photon microscopy to 
investigate cellular trafficking behavior after lung transplantation.
 .Scientific uses of mouse orthotopic lung 
transplantation
Lung transplantation is an established therapy for a variety of 
end-stage pulmonary disease. Importantly, long-term outcome 
after lung transplantation are far worse than those of other solid 
organs (60). Immunologic and non-immunologic mechanisms 
that contribute to acute and chronic graft lung dysfunction 
remain poorly understood and the mouse lung transplantation 
model presents a unique tool that can allow us to study innate 
and adaptive immune responses after lung transplantation. 
Ischemia-reperfusion (I-R) injury-mediated primary graft 
dysfunction (PGD)
PGD is  a  form of  acute lung injur y that  results  f rom 
inflammatory changes induced by I-R injury (61). PGD is graded 
based on PaO2/FiO2 (P/F) ratio and radiographic infiltrates 
assessed at several time points up to 72 hours after transplantation 
(Table 2). By definition this form of injury arises within the first 
72 hours following lung transplantation and is a leading cause 
of early morbidity and mortality after transplantation. PGD is 
characterized by impaired oxygenation and pulmonary edema 
and affects up to 80% of all lung transplant recipients (62-68). 
In addition, PGD has been linked to the development of chronic 
allograft rejection manifested by bronchiolitis obliterans (69). 
Thus, a better knowledge of the pathophysiology of I-R injury 
should facilitate a better understanding of PGD. Biomarker 
phenotyping should become possible in order to develop 
novel therapeutics and reduce the impact of PGD on lung 
transplant outcomes (62). Neutrophils and factors that control 
their production and activation play a critical role in I-R injury. 
Over the last 5 years using the mouse model of orthotopic lung 
Lin et al. Mouse model of orthotopic lung transplantation254
transplantation our group has focused heavily on this cell type. 
We have delineated that neutrophils isolated from the airways 
of lung transplantation recipients stimulate donor dendritic 
cells (DCs) in a contact-dependent fashion to augment their 
production of IL-12 and expand alloantigen-specific IFN-γ(+) T 
cells. DC IL-12 expression is largely regulated by degranulation 
and induced by TNF-α associated with the neutrophil plasma 
membrane. Extended cold ischemic graft storage enhances 
G-CSF-mediated granulopoiesis and neutrophilic graft 
infiltration, resulting in exacerbation of I-R injury after lung 
transplantation. I-R injury prevents immunosuppression-
mediated acceptance of mouse lung allografts unless G-CSF-
mediated granulopoiesis is inhibited (19). In addition, we also 
identified that transcriptional coregulator B cell leukemia/
lymphoma 3 (Bcl3) limits granulopoiesis under inflammatory 
conditions. Bcl3-deficient myeloid progenitors demonstrated 
an enhanced capacity to proliferate and differentiate into 
granulocytes following G-CSF stimulation, whereas the 
accumulation of Bcl3 protein attenuated granulopoiesis in an 
NF-κB p50-dependent manner (70). Future experiments will 
focus on therapeutic strategies to modulate the activation of and 
degranulation of neutrophils in order to ameliorate pulmonary 
graft injury.  
Acute cellular rejection (ACR)
According to the ISHLT Registry, 36% of lung transplant 
recipients experience at least one episode of ACR within 
the first year after transplantation (71). Risk factors for ACR 
remain poorly defined. The degree of major histocompatibility 
antigen (MHC) discordance between donor and recipient has 
been identified as a risk factor in some studies (67-69,72). The 
mouse model of lung transplantation offers an ideal platform 
to study ACR as inbred mouse strains have well defined MHC 
antigens allowing for evaluation of ACR in fully mismatched, 
minor antigen mismatched, and partially matched (by using F1 
crosses as graft donors for example) situations. Since the mouse 
lung transplantation model was established, we have verified 
histopathologically and flow cytometrically that this new animal 
model can recapitulate acute lung allograft rejection successfully 
(1). We have also demonstrated that, similar to other organs 
(73), treatment of lung allografts with anti-CD28-B7 and CD40-
CD40 Ligand co-stimulatory blockade can prolong allograft 
survival indefinitely in several strain combinations (7). Dodd-o 
and colleagues found that anti-CD154 antibody therapy alone 
is sufficient to attenuate ACR in an MHC mismatched mouse 
orthotropic lung transplant model. Improved lung allograft 
acceptance in anti-CD154 Ab treated recipients was associated 
with abrogated CD8+ and CD4+ allospecific effector responses 
and increased frequencies of CD4+CD25+Foxp3+ regulatory 
T-cells in the lung allografts (74). Our group has also provided 
evidence that pulmonary nonhematopoietic cells, through 
their expression of MHC-II, play a critical role in downregulating 
CD4+ T cell-mediated immune responses in vivo (2,4). Obviously, 
this new mouse model will allow for the design of novel studies 
that elucidate mechanisms of ACR and provide rationale for the 
development of therapeutic approaches.
Chronic rejection – Obliterative bronchiolitis (OB)
OB is a form of chronic rejection specific to the lung and is 
characterized by progressive fibrosis and obliteration of the small 
and medium-sized airways of the donor lung (75). The mechanisms 
leading to the development of this condition still remain unclear 
(76). Although lymphocytes are observed in the bronchial wall, the 
prominent cell type found in the BAL is neutrophils (77). Recently, 
evidence suggests the involvement of multiple factors such excessive 
activation of innate immune responses, abnormal angiogenesis and 
failure of appropriate epithelial regeneration and fibroproliferative 
tissue remodeling (78). Laboratory experimentation using animal 
models forms an important component of a “bench-to-bedside-
to-bench” approach that can both increase our understanding 
and lead to the development of novel therapeutic strategies for 
this (76).
Of the several different animal OB models available, each 
has advantages and limitations. There is not an “ideal” model 
Table 2. ISHLT PGD grading schema.





Time points for assessment: T (0 to within 6 hours of reperfusion, 24, 48, and 72 hours). Data from Christie JD, Carby M, Bag R, et al. 
Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International 
Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005;24:1458.
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that precisely reproduces what happens to humans after lung 
transplantation. The lesions of OB are thought to represent the 
shared histological outcome of injury to the airway epithelium 
and subcellular matrix by an array of immune and inflammatory 
insults. From a clinical standpoint, OB remains heterogeneous, 
varying both in timing of onset after transplantation and 
aggressiveness in clinical course (79). So, it is not practical or 
scientifically desirable to test multiple contributing factors at 
the same time.  Pulmonary chronic rejection shares features 
of chronic rejection observed in other solid organ. Chronic 
rejection in all organs mainly manifests as fibrosis in the graft 
resulting in loss of function and eventually grafts loss (80). 
There are several immunologic antigens involved in this fibrosis, 
including major and minor histocompatibility antigens (81) 
as well as self-antigens (82) as both can emerge as targets of 
immune responses after transplantation (83-85).
In theory the orthotopic mouse lung transplantation model 
has great advantages for studying the pathogenesis of OB as 
it offers a physiological model of the human lung transplant 
environment. Lung function and BAL can be assessed at 
various times, various drugs can be tested for efficacy, and 
transgenic and knock-out strains are available to model human 
diseases. However, several physiologic factors in the mouse 
lung anatomy and physiology create potential obstacles in the 
study of OB. The initial OB process starts with a lymphocytic 
infi ltrate of the sub-mucosa of the air ways followed by 
the migration of the lymphocytes through the basement 
membrane into the epithelium (86). At this site, epithelial cell 
necrosis occurs with denudation of mucosa. In the mouse lung, 
there is lack of submucosal glands in the bronchioles, but a 
high numbers of locally resident Clara cells. One of the main 
functions of Clara cells is to protect the bronchiolar epithelium 
from injury. They accomplish this by secreting a variety of 
proteins, including Clara cell secretory protein (CCSP) and a 
solution similar to lung surfactant. They are also responsible 
for detoxifying inhaled harmful substances. Clara cells also act 
as a stem cell and multiply to differentiate into ciliated cells 
that can regenerate bronchiolar epithelium. This is a possible 
reason why mouse airway epithelium remains intact and fully 
differentiated in lung allografts, despite profound vascular 
rejection (7). Since 2007, a few separate groups have tried to 
establish an OB model in the mouse. Although two groups 
have found OB lesions by histology, the experimental design 
and the histological features still need further clarification 
(9,27). Currently we are focusing on three factors that may 
influence the development of OB including: (I) donor and 
recipient strain combinations; (II) time period necessary 
to see chronic rejection in the mouse and; (III) the form of 
immunosuppression that may allow for OB to develop. Once 
established and reproducible, such a model could hold great 
promise for further mechanistic studies and may be used to 
accelerate the development of new strategies for the prevention 
or treatment of pulmonary chronic rejection.
Studies of Non-hematopoietic stromal cells
W hile bone marrow-derived hematopoietic cells, such as 
dendritic cells, play a critical role in pulmonary physiology 
(87-92), we as well as others have focused on the contribution 
of non-hematopoietic cells in pulmonary immune responses 
(4,93). Traditional methods for separating the physiology 
of hematopoietic from non-hematopoietic cells involves the 
creation of bone marrow chimeras by lethal irradiation of a 
recipient mouse followed by reconstitution with bone marrow 
from a mutant strain (94). Donor irradiation, however, may 
change the physiology of non-hematopoietic cells and bone 
marrow chimeras can also suffer from autoimmune disease (4). 
We have recently demonstrated that the transplantation of a 
left lung into a congenic host leads to the rapid substitution 
of donor-derived hematopoietic cells with those of the host, 
leading to the creation of a “chimeric lung graft” in an otherwise 
immunocompetent host. Furthermore, such substitution occurs 
for multiple types of hematopoietic cells such as T cells (4,5) 
and dendritic cells (Figure 9). Such a model can thus be used 
to study both immunology and physiology of pulmonary non-
hematopoietic cells in the absence of irradiation.
 .Conclusions
Although technically difficult, orthotopic lung transplantation 
in the mouse is feasible and reproducible. It has been used for 
multiple scientific avenues of investigation for the last 5 years by 
our laboratory as well as others. Obviously, it is important for 
researchers to understand the physiology behind this model as well 
as its advantages and limitations. Well-designed mouse orthotopic 
lung transplantation experiments provide a great opportunity to 
study mechanisms that affect lung allograft survival and explore 
new therapies for a wide variety of human lung diseases.
Figure 9. Rapid substitution of professional antigen presenting cells, 
such as dendritic cells, occurs after orthotopic lung transplantation.
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